Maximus (NYSE:MMS) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

Maximus (NYSE: MMS) reported Q2 CY2026 revenue of $1.28 billion, down 5.1% year on year and below Wall Street expectations, according to the company. Full-year revenue guidance was $5.28 billion at the midpoint, near analyst estimates. Non-GAAP EPS was $2.22, 0.7% above consensus. The stock fell 3.6% to $60.86 after results.

Original reporting
Published Aug 6, 2026, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 2:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Maximus (NYSE:MMS) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings — source image
Decision brief

The 30-second read

$MMSBearishMed
01

Why it matters

Traders should weigh a Q2 revenue miss and YoY decline against in-line full-year revenue guidance and near-consensus EPS, which together shape expectations for the next quarter’s revenue trajectory.

02

Market read

A Q2 revenue miss versus estimates is the primary negative catalyst, partially offset by close-to-consensus FY revenue guidance and slightly above-consensus non-GAAP EPS.

03

What to watch

Adjusted operating margin held steady (13.2% in Q2) and share count shrank 15%, which can offset revenue weakness and keep EPS trajectory intact if margins remain stable.

Relevance 7/10Novelty 6/10Timing: post-earnings, same-day reaction referenced (stock down 3.6% to $60.86)

Background

Maximus is a government services provider with operational services, clinical assessments, and technology solutions for government agencies.

Company-level read

Ticker impact

$MMSBearishMedium confidence
Context

Maximus reported Q2 CY2026 revenue of $1.28B, down 5.1% YoY, missing Wall Street estimates, while guiding FY revenue to $5.28B midpoint.

Expected impact

Choppy to mildly bearish bias versus expectations, with focus on whether subsequent quarters re-accelerate revenue growth.

Evidence & confidence

The article’s newest decision-relevant facts are the Q2 revenue decline and miss versus estimates, while full-year revenue guidance is close to consensus and EPS is slightly above consensus, which can cushion the selloff.

Market effects

Signals continued pressure on government services revenue growth, even as margins and EPS remain relatively supported.

No specific regional market linkage beyond US government services demand.

Limited; the article frames operations across the US and internationally but provides no region-specific drivers.

Counterpoint

The full-year revenue midpoint ($5.28B) is close to analysts’ estimates and non-GAAP EPS ($2.22) is slightly above consensus, implying the market may be over-penalizing a single-quarter softness.

Key entities

  • Maximus

    Government services provider reporting Q2 CY2026 results and full-year revenue guidance.

Related articles

$MMSMed

Maximus Q3 Earnings Call Highlights

Maximus (NYSE:MMS) reported Q3 results and guidance on an earnings call. Revised guidance implies adjusted diluted EPS of $1.91 at the midpoint and ~13% adjusted EBITDA margin, with incentive eligibility paused through Dec. 31, 2026. U.S. Federal Services revenue was $721M, U.S. Services $418M, and Outside the U.S. $140M. Total debt was $1.65B, net leverage 2.0x, and it repurchased 750k shares for $50M.

$MMSMed

MAXIMUS, INC. (MMS): Results of Operations and Financial Condition

MAXIMUS, INC. (MMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mms-2026x06x30x8kxex991.htm EX-99.1 Document FOR IMMEDIATE RELEASE CONTACT: James Francis, VP - IR IR@maximus.com Date: August 6, 2026 Maximus Reports Fiscal Year 2026 Third Quarter Results Strong earnings performance reflects disciplined execution (Tysons, Va. - August

$MMSMedAI 8/10

Maximus Cuts FY26 Adj. EPS Outlook; Stock Down 5% - Update

Maximus, Inc. (MMS) reported third-quarter results and cut its FY2026 adjusted EPS outlook to $7.90-$8.20 per share from $8.25-$8.55, citing a temporary contractual change on a major federal program. It kept FY2026 sales guidance at $5.20 billion-$5.35 billion, toward the lower end. Shares were down about 5% premarket to $59.86.

$NVOMedAI 8/10

Novo Nordisk A/S Q2 Earnings Call Highlights

Novo Nordisk reported Q2 adjusted sales of DKK 78.5 billion, with obesity care sales up 16% and GLP-1 diabetes up 2%. Adjusted gross margin fell to 78.2% from 82.7% due to lower prices, about DKK 3 billion one-time manufacturing-cost items, and FX. The company raised 2026 outlook to 0% to -6% adjusted sales and operating profit growth. ZEUS ziltivekimab trial missed its primary endpoint (HR 0.99).

$NYTMed

New York Times Q2 Earnings Call Highlights

The New York Times Company (NYSE:NYT) reported Q2 results on its earnings call. Digital-only subscribers rose 13.3% YoY and digital-only ARPU increased 3.1%. First-half free cash flow was about $266M and the company returned about $160M to shareholders. It guided Q3 digital-only subscription revenue up 12% to 15% and digital ad revenue up mid- to high-teens.

$OCMed

Owens Corning Q2 Earnings Call Highlights

Owens Corning (NYSE:OC) said Iran-related net cost impact is expected to be about $40 million in Q3, with roofing the most affected segment. The company reported Q2 liquidity of $1.8 billion and plans to repay $400 million of senior notes in Q3. Full-year capex is about $800 million. Roofing Q2 sales were ~$1.3 billion; insulation revenue rose 4% to $971 million.